An open-label, multicenter, noncomparative safety and efficacy study of Mircette™, a low-dose estrogen-progestin oral contraceptive
- 31 July 1998
- journal article
- clinical trial
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 179 (1) , S2-S8
- https://doi.org/10.1016/s0002-9378(98)70290-x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Ovarian activity in women taking an oral contraceptive containing 20 μg ethinyl estradiol and 150 μg desogestrel: Effects of low estrogen doses during the hormone-free intervalAmerican Journal of Obstetrics and Gynecology, 1998
- Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptomsObstetrics & Gynecology, 1997
- Inhibition of ovulation by an oral contraceptive containing 100 μg levonorgestrel in combination with 20 μg ethinylestradiolContraception, 1996
- Desogestrel, Norgestimate, and Gestodene: The Newer ProgestinsAnnals of Pharmacotherapy, 1995
- Combined oral contraception with desogestrel/ethinyl estradiol: Tolerability profileAmerican Journal of Obstetrics and Gynecology, 1993
- Clinical experience and pharmacological effects of an oral contraceptive containing 20μg oestrogenContraception, 1992
- Oral contraceptives and cycle control: A critical review of the literatureAdvances in Contraception, 1992
- Clinical experience with a modern low-dose oral contraceptive in almost 100,000 usersContraception, 1991
- Phase III clinical trial with a new oral contraceptive containing 150 μg desogestrel and 20 μg ethinylestradiolActa Obstetricia et Gynecologica Scandinavica, 1991
- Long-term experience with a low-dose oral contraceptiveGynecological Endocrinology, 1990